10-Q: Edwards Lifesciences Q3: Sales Up, EPS Down Amid Legal & Tax Battles

Edwards Lifesciences reports increased Q3 sales driven by TAVR and TMTT products, but diluted EPS declined due to higher expenses, impairment charges, and significant litigation and tax disputes.

Summary

• Net sales for the nine months ended September 30, 2025, increased by $444.3 million to $4.5 billion, primarily driven by TAVR and TMTT products.
• Diluted earnings per share from continuing operations decreased to $1.70 for the nine months ended September 30, 2025, from $1.75 in the prior year.
• Gross profit increased for the three and nine months ended September 30, 2025, but gross profit as a percentage of net sales decreased due to foreign currency fluctuations and higher operational expenses.
• Operating income for the nine months ended September 30, 2025, was $1,113.1 million, up from $1,066.1 million in the prior year.
• Incurred $116.8 million in certain litigation expenses for the nine months ended September 30, 2025, compared to $27.8 million in the prior year.
• Recognized a $40.0 million intangible assets impairment charge and a $47.1 million loss on impairment from not exercising an acquisition option during the nine months ended September 30, 2025.
• The effective income tax rate increased to 16.1% for the nine months ended September 30, 2025, from 9.2% in the prior year, partly due to the global minimum tax (Pillar Two) expected to result in an additional $50 million tax expense in 2025.
• Repurchased 11.2 million shares for $844.9 million during the nine months ended September 30, 2025, with $2.1 billion remaining under the share repurchase program.
• Acquired the remaining 39% noncontrolling interest in Vectorious Medical Technologies for $233.7 million, increasing ownership to 100%.

Sentiment

Score: 4

Explanation: While sales growth in key product areas is strong and new product approvals are positive, the significant decline in diluted EPS, increased litigation and R&D expenses, substantial impairment charges, and ongoing regulatory/tax challenges create a negative sentiment. The FTC blocking an acquisition adds further uncertainty.

Positives

• Net sales increased by 11.0% to $4.5 billion for the nine months ended September 30, 2025, driven by strong product performance.
• Transcatheter Aortic Valve Replacement (TAVR) sales increased by 8.4% to $3,327.4 million for the nine months ended September 30, 2025, primarily due to higher sales of the SAPIEN 3 Ultra RESILIA valve.
• Transcatheter Mitral and Tricuspid Therapies (TMTT) sales surged by 59.8% to $394.9 million for the nine months ended September 30, 2025, driven by the PASCAL system and EVOQUE tricuspid valve replacement system launch.
• Surgical Structural Heart sales increased by 5.3% to $775.7 million for the nine months ended September 30, 2025, with strong performance from INSPIRIS RESILIA, MITRIS RESILIA, and KONECT RESILIA valves.
• Received United States FDA approval for the SAPIEN 3 platform for severe aortic stenosis patients without symptoms in April 2025.
• Received CE Mark for the Edwards SAPIEN M3 mitral valve replacement system in April 2025.
• Received CE Mark for the KONECT RESILIA aortic valved conduit in June 2025.
• Net cash provided by operating activities increased by $474.5 million to $1,144.3 million for the nine months ended September 30, 2025, due to lower tax payments and improved operating performance.
• The Israel Tax Authority formally withdrew its $110 million 2017 assessment on July 31, 2025.

Negatives

• Diluted earnings per share from continuing operations decreased to $1.70 for the nine months ended September 30, 2025, from $1.75 in the prior year.
• Gross profit as a percentage of net sales decreased for the three and nine months ended September 30, 2025, due to foreign currency rate fluctuations and higher operational expenses.
• Selling, general, and administrative (SG&A) expenses increased by $185.0 million to $1,482.3 million for the nine months ended September 30, 2025, driven by personnel costs, performance-based compensation, and professional services.
• Research and development (R&D) expenses increased by $29.6 million to $811.5 million for the nine months ended September 30, 2025, due to increased clinical activity and higher performance-based compensation.
• Incurred $116.8 million in certain litigation expenses for the nine months ended September 30, 2025, a significant increase from $27.8 million in the prior year.
• Recorded a $40.0 million intangible assets impairment charge in August 2025 due to assets no longer expected to generate future economic benefit.
• Recognized a $47.1 million loss on impairment in June 2025 from deciding not to exercise an option to acquire a medical device company due to slower than anticipated progress.
• The effective income tax rate increased to 16.1% for the nine months ended September 30, 2025, from 9.2% in the prior year, partly due to the global minimum tax (Pillar Two) and decreased tax benefit from employee share-based compensation.
• The United States Federal Trade Commission moved to block the proposed acquisition of JenaValve Technology, Inc. in August 2025, alleging anticompetitive concerns.

Risks

• The United States Federal Trade Commission (FTC) moved to block the proposed acquisition of JenaValve Technology, Inc. in August 2025, alleging anticompetitive concerns, with a final court determination estimated by the end of Q1 2026.
• Ongoing patent infringement lawsuit by Aortic Innovations LLC regarding the SAPIEN 3 Ultra product, with the Federal Circuit affirming the district court's claim construction in favor of the Company on October 27, 2025, but remaining claims are proceeding.
• The European Commission is investigating certain business practices, including the unilateral pro-innovation (anti-copycat) policy and patent practices, with an unpredictable outcome.
• A lawsuit filed by Fortis Advisors, LLC alleging breach of the Agreement and Plan of Merger related to Harpoon Medical, Inc., seeking acceleration and payment of all contingent milestone payments, with trial scheduled for December 2025.
• A putative securities class action (Patel v. Edwards Lifesciences Corporation) and consolidated shareholder derivative actions (Ho Action and Sheridan Action) alleging violations of securities laws and breaches of fiduciary duties, with a motion to dismiss granted in part and denied in part on September 19, 2025.
• Significant uncertain tax positions with the IRS, including a Notice of Proposed Adjustment (NOPA) for 2015-2017 tax years relating to transfer pricing, seeking an additional $269.3 million in tax, which the Company plans to vigorously contest through judicial process.
• Similar material tax disputes may arise for the 2018 through 2024 tax years regarding Surgical/TAVR intercompany royalty transactions, which remain subject to IRS examination.
• The Israel Tax Authority (ITA) reserves the right to evaluate whether intellectual property was transferred in later years, despite withdrawing its 2017 assessment, and has a pending assessment for 2018-2022 tax years for $16 million, which the Company is appealing.
• Exposure to investment risks related to changes in the underlying financial condition and credit capacity of its $1,223.2 million in debt securities and $207.9 million in equity instruments of public and private companies.
• Dependence on physicians, research institutions, and hospital systems, competition, reliance on vendors, and potential damage to information technology systems are ongoing risks.

Future Outlook

The Company expects the global minimum tax (Pillar Two) provisions to result in additional tax expense of approximately $50 million in 2025. It intends to continue pursuing regulatory approval for the JenaValve acquisition, with a final court determination estimated by the end of the first quarter of 2026. The Company will continue to evaluate the potential effects of the One Big Beautiful Bill Act (OBBBA) on future periods. Remaining severance obligations from the September 2024 workforce realignment are expected to be substantially paid by the end of 2025. The sale of a non-core product group is expected to close in the fourth quarter of 2025.

Management Comments

• We are the leading global structural heart disease innovation company, driven by a passion to improve patient lives.
• Through breakthrough technologies, world-class evidence, and partnerships with clinicians and healthcare stakeholders, our employees are inspired by our patient-focused culture to deliver life-changing innovations to those who need them most.
• Our vision for growth is to treat patients with both valvular and non-valvular structural heart disease, such as heart failure, which is a natural progression of the disease for many patients suffering from aortic stenosis and mitral and tricuspid regurgitation.
• We are dedicated to generating robust clinical, economic, and quality-of-life evidence that is increasingly expected by patients, clinicians, and payors in the current healthcare environment, with the goal of encouraging the adoption of innovative new medical therapies that demonstrate superior outcomes.
• We are committed to developing new technologies and innovations, and we are committed to defending our intellectual property in support of those developments.

Industry Context

The medical technology industry is highly competitive and continues to evolve, with an increasing expectation from patients, clinicians, and payors for robust clinical, economic, and quality-of-life evidence for new medical therapies. Edwards Lifesciences is positioning itself as a leader in structural heart disease innovation, expanding its focus to include non-valvular conditions like heart failure, which aligns with the natural progression of disease for many patients. The company's strategic divestitures of non-core businesses (Critical Care and another non-core product group) indicate a sharpened focus on implantable medical innovations for structural heart disease.

Management Changes

Corporate Governance

Legal Proceedings

• Aortic Innovations LLC filed a patent infringement lawsuit against Edwards Lifesciences regarding the SAPIEN 3 Ultra product. The Federal Circuit affirmed the district court's claim construction in favor of the Company on October 27, 2025, but remaining claims are proceeding.
• The European Commission is investigating certain business practices of Edwards, including its unilateral pro-innovation (anti-copycat) policy and patent practices.
• Fortis Advisors, LLC filed suit alleging breach of the Agreement and Plan of Merger related to Harpoon Medical, Inc., seeking acceleration and payment of all contingent milestone payments. Trial is scheduled for December 2025.
• Patel v. Edwards Lifesciences Corporation, a putative securities class action, alleges violations of securities laws based on alleged false or misleading statements. The Court granted in part and denied in part the motion to dismiss on September 19, 2025.
• Ho v. Zovighian, et al. and Sheridan v. Zovighian, et al., consolidated shareholder derivative actions, allege violations of federal securities laws, breaches of fiduciary duties, and other claims, based on the same facts as the Securities Class Action.
• The Company has accrued an aggregate estimated liability of $85.5 million for outstanding legal proceedings as of September 30, 2025.
• The IRS issued a Notice of Proposed Adjustment (NOPA) for 2015-2017 tax years relating to transfer pricing, proposing a substantial increase to United States taxable income, which could result in additional tax expense of approximately $255 million. The Company plans to vigorously contest this through judicial process, with an additional $269.3 million sought in excess of its filing position.
• Surgical/TAVR intercompany royalty transactions for tax years 2018 through 2024 remain subject to IRS examination, with potential for similar material tax disputes.
• The Israel Tax Authority (ITA) withdrew its $110 million 2017 assessment but reserves the right to evaluate intellectual property transfer in later years. The ITA also issued a $16 million assessment for 2018-2022, which the Company is appealing and expects to be withdrawn.

Related Party Transactions

• The Company has equity investments in unconsolidated entities and variable interest entities (VIEs), including promissory notes and options to acquire, which could result in future cash outlays. Examples include loans to JenaValve Technology, Inc. ($75.0 million advanced as of Sep 30, 2025, with an additional $7.5 million in Oct 2025) and another privately-held medical device company (total $45.0 million advanced as of Sep 30, 2025, with an additional $15.0 million in Oct 2025).

Stakeholder Impact

• Shareholders: Experienced a decrease in diluted EPS, but the ongoing share repurchase program (with $2.1 billion remaining authority) may provide some support. Significant legal and tax disputes introduce uncertainty and potential financial liabilities.
• Employees: A global workforce realignment in September 2024 impacted approximately 2% of employees, resulting in severance expenses. Stock-based compensation remains a significant component of overall compensation.
• Customers/Patients: Benefit from continued innovation and new product approvals (SAPIEN 3, PASCAL, EVOQUE, INSPIRIS RESILIA, MITRIS RESILIA, KONECT RESILIA), expanding treatment options for structural heart disease.
• Suppliers/Vendors: The Company's reliance on vendors, suppliers, and other third parties is noted as a risk factor, indicating potential impact from supply chain disruptions or changes in relationships.
• Creditors: The Company maintains a strong liquidity position with no amounts outstanding under its $750.0 million revolving credit facility, but has $598.2 million in long-term debt (2018 Notes).

Next Steps

• Continue to pursue regulatory approval for the acquisition of JenaValve Technology, Inc., with an estimated final court determination by the end of the first quarter of 2026.
• Vigorously defend against the Aortic Innovations LLC patent infringement lawsuit, with remaining claims proceeding after a favorable Federal Circuit ruling on claim construction.
• Cooperate with the European Commission's investigation into business practices while defending the Company's position.
• Vigorously defend against the Fortis Advisors, LLC litigation, with trial scheduled for December 2025.
• Defend against the consolidated securities class action and shareholder derivative actions.
• Vigorously contest the IRS's claim for an additional $269.3 million in tax for 2015-2017 through the judicial process and address potential similar disputes for 2018-2024 tax years.
• Continue to appeal the Israel Tax Authority's $16 million assessment for 2018-2022 and defend against any future intellectual property transfer claims.
• Evaluate the potential effects of the One Big Beautiful Bill Act (OBBBA) on future periods.
• Complete the sale of the non-core product group, expected to close in the fourth quarter of 2025.
• Scott B. Ullem will transition from CFO to Strategic Advisor, with his full-time employment ending June 30, 2026, and the Encore Period concluding June 30, 2028.

Key Dates

Recommendation

Edwards Lifesciences demonstrates strong sales growth and continued innovation in its core structural heart disease segments, evidenced by new product approvals and increased TAVR and TMTT sales. However, the company faces significant headwinds, including a decline in diluted EPS, a decrease in gross profit margin, substantial increases in litigation and R&D expenses, and notable impairment charges. The FTC's move to block a key acquisition and ongoing, material tax disputes with the IRS and ITA introduce considerable regulatory and financial uncertainty. While the share repurchase program provides some capital return, the combination of profitability pressures and unresolved legal/tax issues suggests a 'hold' recommendation, as the positive growth drivers are currently offset by significant risks and uncertainties that could impact future financial performance.

Keywords

Edwards Lifesciences, Medical Devices, Structural Heart Disease, TAVR, Transcatheter Aortic Valve Replacement, TMTT, Transcatheter Mitral and Tricuspid Therapies, Surgical Structural Heart, SEC Filing, 10-Q, Financial Results, Corporate Governance, Risk Factors, Litigation, Tax Disputes, Acquisition, FDA Approval, CE Mark, Share Repurchase